DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,372 filers reported holding DANAHER CORPORATION in Q1 2019. The put-call ratio across all filers is 1.02 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $3,648,810 | +100.1% | 14,604 | +100.0% | 0.43% | -3.6% |
Q1 2024 | $1,823,455 | +7.9% | 7,302 | 0.0% | 0.45% | -3.9% |
Q4 2023 | $1,689,245 | +91.4% | 7,302 | +105.3% | 0.46% | +35.3% |
Q3 2023 | $882,492 | +3.4% | 3,557 | 0.0% | 0.34% | +8.9% |
Q2 2023 | $853,680 | -4.8% | 3,557 | 0.0% | 0.32% | -12.0% |
Q1 2023 | $896,506 | -6.1% | 3,557 | -1.1% | 0.36% | -13.1% |
Q4 2022 | $954,716 | +1.3% | 3,597 | -1.4% | 0.41% | -3.7% |
Q3 2022 | $942,000 | +1.2% | 3,647 | -0.7% | 0.43% | +10.0% |
Q2 2022 | $931,000 | -13.6% | 3,672 | 0.0% | 0.39% | +8.4% |
Q1 2022 | $1,077,000 | -10.8% | 3,672 | 0.0% | 0.36% | +0.6% |
Q4 2021 | $1,208,000 | +3.2% | 3,672 | -4.4% | 0.36% | -7.5% |
Q3 2021 | $1,170,000 | +16.2% | 3,842 | +2.4% | 0.39% | +15.9% |
Q2 2021 | $1,007,000 | +19.2% | 3,752 | 0.0% | 0.33% | +9.9% |
Q1 2021 | $845,000 | +1.4% | 3,752 | 0.0% | 0.30% | -6.2% |
Q4 2020 | $833,000 | +3.0% | 3,752 | -0.2% | 0.32% | -3.3% |
Q3 2020 | $809,000 | +21.7% | 3,758 | 0.0% | 0.33% | +12.8% |
Q2 2020 | $665,000 | +27.9% | 3,758 | 0.0% | 0.30% | +0.7% |
Q1 2020 | $520,000 | -9.9% | 3,758 | 0.0% | 0.29% | +19.0% |
Q4 2019 | $577,000 | +6.3% | 3,758 | 0.0% | 0.25% | -2.4% |
Q3 2019 | $543,000 | +1.9% | 3,758 | +0.8% | 0.25% | +4.5% |
Q2 2019 | $533,000 | +8.3% | 3,730 | 0.0% | 0.24% | +2.5% |
Q1 2019 | $492,000 | +27.8% | 3,730 | 0.0% | 0.24% | +12.4% |
Q4 2018 | $385,000 | -7.9% | 3,730 | -3.1% | 0.21% | +11.7% |
Q3 2018 | $418,000 | +10.0% | 3,850 | 0.0% | 0.19% | +1.6% |
Q2 2018 | $380,000 | +0.8% | 3,850 | 0.0% | 0.18% | -0.5% |
Q1 2018 | $377,000 | +5.6% | 3,850 | 0.0% | 0.19% | +6.3% |
Q4 2017 | $357,000 | +8.2% | 3,850 | 0.0% | 0.18% | +1.7% |
Q3 2017 | $330,000 | +1.5% | 3,850 | 0.0% | 0.17% | 0.0% |
Q2 2017 | $325,000 | -1.2% | 3,850 | 0.0% | 0.17% | +3.0% |
Q1 2017 | $329,000 | +9.7% | 3,850 | 0.0% | 0.17% | -37.2% |
Q4 2016 | $300,000 | -0.7% | 3,850 | 0.0% | 0.27% | -11.9% |
Q3 2016 | $302,000 | -22.4% | 3,850 | 0.0% | 0.30% | -23.0% |
Q2 2016 | $389,000 | +6.6% | 3,850 | 0.0% | 0.39% | +12.6% |
Q1 2016 | $365,000 | +2.0% | 3,850 | 0.0% | 0.35% | -2.0% |
Q4 2015 | $358,000 | +9.1% | 3,850 | 0.0% | 0.36% | +2.9% |
Q3 2015 | $328,000 | -0.6% | 3,850 | 0.0% | 0.34% | +2.4% |
Q2 2015 | $330,000 | +0.9% | 3,850 | 0.0% | 0.34% | +1.5% |
Q1 2015 | $327,000 | -0.6% | 3,850 | 0.0% | 0.33% | -1.2% |
Q4 2014 | $329,000 | – | 3,850 | – | 0.34% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
Third Point | 3,570,000 | $494,124,000 | 7.88% |